About entrectinib
TRK and ROS1 kinase inhibitor
Used for
- Treats certain advanced cancers with NTRK gene fusions.
- Treats ROS1-positive non-small cell lung cancer in adults.
Usual adult dose
600 mg by mouth once daily for adults, with or without food.
Usual dose in children
For NTRK fusion-positive solid tumors: 300 mg daily under 3 years; 400 mg daily ages 3–12; 600 mg daily over 12.
Common side effects
- Fatigue, dizziness, or changes in taste
- Constipation, diarrhea, nausea, or vomiting
- Swelling, weight gain, or muscle pain
- Vision changes or cognitive effects
Important warnings
- Can cause heart failure, fractures, or QT prolongation.
- May cause dizziness, fainting, or impaired driving.
- Can cause liver problems; monitoring may be needed.
- May harm an unborn baby; effective contraception is advised.
Pregnancy
May cause fetal harm. Avoid during treatment and for five weeks after the final dose.
Breastfeeding
Do not breastfeed during treatment or for seven days after the final dose.
Interactions
- Strong or moderate CYP3A inhibitors can raise entrectinib levels.
- Strong or moderate CYP3A inducers can lower entrectinib levels.
- Avoid grapefruit and grapefruit juice, which can increase drug levels.
- Entrectinib may affect medicines metabolized by CYP3A or CYP2C9.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.